Watch out for a scary new family of mind-robbing cholesterol drugs

Watch out for a scary new family of mind-robbing cholesterol drugs

Dear Reader,

There’s a new class of cholesterol drugs coming to your neighborhood pharmacy.

And you need to know about it even before it arrives.

Because if your doctor tries to give you an Rx for one of these latest high-tech meds — called PCSK9 blockers — to lower your cholesterol, don’t just walk…run to another doctor.

Big Pharma is calling these drugs “the next big leap” in cholesterol treatments. But what they should be called is the next big leap in the number of people with dementia.

Think of them as biological weapons in a new kind of arms race. And they’re about as dangerous as drugs come.

In this race are drug makers Sanofi, Amgen and Regeneron, all hoping to rake in billions with a whole new way to lower your cholesterol.

These novel drugs work by blocking a protein called PCSK9. That allows more cholesterol to be sent to your liver to be removed.

Only now it appears they will do away with more than cholesterol.

A lot more.

How about your memory? Or ability to think or understand or remember things?

The way these meds can affect you is looking more and more like a ‘no-brainer’.

Researchers got the idea for them about 10 years ago when they discovered that people who have very low cholesterol numbers were naturally blocking this protein.

But what they ignored is…those are sick people! It’s not normal or healthy to have such low cholesterol. That puts you at risk for all kinds of diseases, including stroke, depression and suicide

.
Yet for the last decade researchers have been working on figuring out how to get everyone else to block that protein, too. They want to lower your cholesterol at any cost, even if it means stealing your memory — and your memories.

Believe it or not, the risk is so great that it even raised a red flag at the FDA. In fact, two of the companies developing these meds received letters from the FDA warning that it’s aware of “neurocognitive adverse events” with these PCSK9 drugs. In other words, it’s concerned that once they hit the market thousands could come down with symptoms of dementia.

But the manufacturers don’t really see this as a “problem” and said they have no idea how the FDA learned about such side effects. They have agreed to “look for it carefully,” though.

Yeah, right.

They also claimed any bad effects on the brain were news to them. “We’re not aware of any safety concern right now,” was the response of one executive.

And that FDA “warning” letter didn’t seem to cause too much concern, either. It was merely a “mini crisis” that has already been resolved, according to industry sources.

The FDA may be going through the motions of pretending to be doing its job. But it’s not likely to delay the approval of these drugs.

That’s because there are billions of dollars at stake in getting them out ASAP. And little things like your ability to think and remember certainly won’t be allowed to stand in the way.

Sources:

“Tomorrow’s cardio blockbusters: Inside ‘the next big leap’ in controlling cholesterol” Damian Garde, March 31, 2014, FierceBiotech, fiercebiotech.com